MDGEF (Medigene AG) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MDGEF Medigene AG MDGEF
12 GF Score
Price $2.59
View Full Analysis

What is Medigene AG 5-Year Yield-on-Cost %?

Medigene AG MDGEF 12 5-Year Yield-on-Cost % is 0.00 as of Jul. 17, 2026. GuruFocus rates MDGEF with a GF Score™ of 12/100.

Medigene AG's yield on cost for the quarter that ended in Jun. 2024 was 0.00.


The historical rank and industry rank for Medigene AG's 5-Year Yield-on-Cost % or its related term are showing as below:



MDGEF's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.73
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Medigene AG  (OTCPK:MDGEF) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

Medigene AG 5-Year Yield-on-Cost % Related Terms

MDGEF vs VRTX, REGN, ALNY: 5-Year Yield-on-Cost % Comparison

For the Biotechnology subindustry, Medigene AG's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Medigene AG 5-Year Yield-on-Cost % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Medigene AG's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Medigene AG's 5-Year Yield-on-Cost % falls into.


MDGEF
12GF Score
Medigene AG MDGEF
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medigene AG 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Medigene AG is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Medigene AG (MDGEF) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 17, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Medigene AG and its competitors.
Is Medigene AG's 5-Year Yield-on-Cost % too high?
Medigene AG's current 5-Year Yield-on-Cost % is 0.00. Overall, Medigene AG has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Medigene AG's 5-Year Yield-on-Cost % compare to VRTX and REGN?
Medigene AG's 5-Year Yield-on-Cost % of 0.00 can be compared against companies in the Biotechnology industry. The industry median 5-Year Yield-on-Cost % is 1.73. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.73, based on 152 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Medigene AG and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medigene AG's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigene AG stock overvalued right now?
Medigene AG (MDGEF) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Medigene AG's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Medigene AG (MDGEF), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Medigene AG Business Description

Address Lochhamer Strasse 11, Martinsried, Planegg, BY, DEU, 82152
Medigene AG is an immuno-oncology biotechnology company. focused on developing differentiated T Cell Receptor engineered T cell (TCR-T) therapies for the treatment of multiple solid tumor indications with a high unmet medical need. The operating segments of the organization are Immunotherapies and Other products. Immunotherapies consist of T-cell receptor-based adoptive T-cell therapy and DC vaccines. The group operates in the United States, Germany, and Asia, of which the majority of the revenue is derived from operations in Germany.
12GF Score

Get the complete analysis for MDGEF

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.59
Price